NewLimit vs Mirador Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $130M Series B (Kleiner Perkins) + $45M from Eli Lilly at $1.62B valuation. First demonstrated restoration of youthful killing function in aged human CD8 T cells.
About
NewLimit is a longevity biotechnology company that demonstrated the first-ever restoration of youthful killing function in aged human CD8 T cells using transcription factor payloads — a major biological milestone with implications for cancer immunotherapy and immune aging. The company raised $130 million in Series B financing led by Kleiner Perkins, followed by $45 million in additional financing from Eli Lilly at a $1.62 billion valuation, with clinical studies in planning.
Raised $250M Series B (Jan 2026). $650M+ total raised. Mirador360 genetics-first platform. 10+ clinical readouts by end of 2027. Pipeline spans Crohn's, ulcerative colitis, RA, IPF.
About
Mirador Therapeutics is a precision immunology company with a genetics-first platform (Mirador360) that uses human genetic data to identify the most biologically validated targets and patient subpopulations for inflammatory and fibrotic diseases. The company closed a $250 million Series B in January 2026, bringing total funding above $650 million, with an ambitious pipeline targeting Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis (IPF). Ten or more clinical readouts are expected by end of 2027.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.